CIELO Study for Autoimmune Encephalitis

I'm Interested!

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-METHYL-D-ASPARTIC ACID RECEPTOR (NMDAR) OR ANTI-LEUCINE-RICH GLIOMA-INACTIVATED 1 (LGI1) ENCEPHALITIS

Sex at Birth: Any
Age: Child (Birth - 17), Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied: Brain and Nervous System, Encephalitis

Study Purpose

The purpose of this study is to assess the effects, good or bad, of satralizumab in participants with autoimmune encephalitis. You are being asked to take part in this research study (also known as a clinical trial) because you have autoimmune encephalitis, a disease where the body's immune system attacks the brain.